Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Hospital

Distinct Healthcare IPO Hong Kong: Private Provider Seeks $36M HKEX Listing

Fineline Cube Jan 29, 2026
Company Deals

Biogen’s Litifilimab Secures FDA Breakthrough Therapy Designation for Lupus

Fineline Cube Jan 29, 2026
Company Deals

Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal

Fineline Cube Jan 29, 2026
Company Deals

Apeloa Partners with MindRank on AI Drug Development Platform

Fineline Cube Jan 28, 2026
Company Deals Medical Device

IVD Medical Launches Nipah Virus Detection Kit with AI Early Warning Platform

Fineline Cube Jan 28, 2026
Policy / Regulatory

FDA Removes Suicide Warnings from GLP‑1 Drugs After Investigation Finds No Causal Link

Fineline Cube Jan 28, 2026
Company Drug

MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study

Fineline Cube Jan 29, 2026
Company Drug

Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo

Fineline Cube Jan 29, 2026
Company Drug

Fosun Pharma’s LBP-ShC4 Receives FDA Approval for Androgenic Alopecia Study

Fineline Cube May 12, 2025

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196, SHA: 600196) announced that it has...

Company Medical Device

MicroPort’s Talos Stent Gains Marketing Approval in Argentina

Fineline Cube May 12, 2025

Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016) announced that it has received marketing approval...

Policy / Regulatory

Hainan Unveils 20 Measures to Boost Pharmaceutical Industry Reform and Quality

Fineline Cube May 12, 2025

The General Office of the People’s Government of Hainan Province has released the “Implementation Plan...

Company Deals

Minghui Pharmaceutical Signs Licensing Deal with Qilu for B7-H3 ADC Development

Fineline Cube May 12, 2025

China-based Minghui Pharmaceutical has entered into an exclusive licensing and collaboration agreement with Qilu Pharmaceutical....

Company Deals

EnChannel Medical Secures RMB 600 Million in Series B Funding for Electrophysiological Products

Fineline Cube May 12, 2025

China-based EnChannel Medical Guangzhou Inc., a specialist in electrophysiology, has reportedly secured RMB 600 million...

Company Drug

Hansoh Pharma’s Ameile Wins Fourth NMPA Approval for NSCLC Treatment

Fineline Cube May 12, 2025

China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its epidermal growth factor receptor...

Company Deals

Eli Lilly and Purdue Expand Partnership With $250 Million Investment

Fineline Cube May 12, 2025

US-based Eli Lilly & Co. (NYSE: LLY) and Purdue University have expanded their long-term partnership...

Company Drug

CARsgen Therapeutics’ CT0596 Shows Promising Results in Early Clinical Study

Fineline Cube May 12, 2025

China-based CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced preliminary clinical data for CT0596, an allogeneic...

Company Drug

CSPC Receives FDA Approval for SYH2046 in Heart Failure After Acute Myocardial Infarction

Fineline Cube May 12, 2025

China-based CSPC Pharmaceutical Group Co., Ltd (HKG: 1093) announced that it has received approval from...

Company Drug

UCB Gets Japanese Approval for New Administration Routes of Rystiggo in gMG

Fineline Cube May 12, 2025

Belgium-based biopharma UCB (EBR: UCB) announced that it has received marketing approval from Japan’s Pharmaceuticals and...

Company Deals Drug

Shanghai Escugen Partners with ConjugateBio on EZWi-Fit Platform for ADC Development

Fineline Cube May 12, 2025

China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding...

Company Drug

InnoCare Pharma’s Mesutoclax Granted Breakthrough Therapy Designation for R/R MCL

Fineline Cube May 12, 2025

Beijing-based biotech InnoCare Pharma (HKG: 9969, SHA: 688428) announced that the Center for Drug Evaluation...

Company

AstraZeneca Breaks Ground on New Small Molecule Drug Plant in Wuxi

Fineline Cube May 12, 2025

UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) has commenced the construction of a new small...

Company Drug

IASO Biotherapeutics’ Fucaso Granted Orphan Drug Designation by SFDA for Multiple Myeloma

Fineline Cube May 12, 2025

China-based IASO Biotherapeutics announced that the Saudi Food and Drug Authority (SFDA) has granted Orphan...

Company Drug

Lepu Medical’s MWN109 Gets NMPA Clinical Approval for Diabetes and Obesity

Fineline Cube May 12, 2025

China-based Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a provider of cardiovascular disease solutions,...

Company Drug

RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis

Fineline Cube May 12, 2025

China-based biopharma RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) has...

Company Drug

NMPA Grants Hengrui Pharmaceuticals Approval for Adebrelimab Combination Trials

Fineline Cube May 12, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received approval from...

Company Deals

XtalPi Holdings Plans Acquisition of Re Medical for RMB 250 Million

Fineline Cube May 12, 2025

Shenzhen-based XtalPi Holdings Limited (HKG: 2228) announced plans to acquire a 90% stake in Re...

Company Medical Device

Sino Medical Sciences Gains Mexican Approval for Coronary Balloon Catheters

Fineline Cube May 12, 2025

China-based Sino Medical Sciences Technology Inc. (SHA: 688108) announced that it has received marketing approval...

Company Drug

Abogen’s ABO2102 mRNA Cancer Vaccine Gets US Clinical Trial Approval

Fineline Cube May 9, 2025

China’s Abogen Biosciences Co., Ltd, a developer of messenger ribonucleic acid (mRNA) drugs, announced that...

Posts pagination

1 … 114 115 116 … 616

Recent updates

  • MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study
  • Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo
  • Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%
  • Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis
  • Danaher Q4 Revenue Grows 3% to $24.6B on Biotech and Diagnostics Innovation
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

MicuRx MRX-5 Gets FDA Nod for Phase II NTM Lung Disease Study

Company Drug

Huiyu Pharma HYP-6589 Gets NMPA Nod for NSCLC Osimertinib Combo

Company

Servier Oncology Revenue Drives 16% Growth, US Sales Surge 70%

Company Drug

Changchun High‑Tech’s Firsekibart Filing Accepted for Non‑Infectious Uveitis

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.